

75786_Auto_Edited.docx

Name of Journal: *World Journal of Radiology*

Manuscript NO: 75786

Manuscript Type: SYSTEMATIC REVIEWS

Catheter-based Renal Sympathetic Nerve Denervation on Hypertension Management Outcomes

Som P Singh, Kevin J Varghese, Fahad M Qureshi, Macy C Anderson, John Foxworth, Mark M Knuepfer

Abstract

BACKGROUND

Renal sympathetic denervation (RSD) provides a minimally invasive interventional treatment modality for patients with resistant hypertension. However, the post-operative outcomes remain a key area of investigation since its earliest clinical trials.

AIM

To evaluate patient outcomes after RSD intervention among peer-reviewed patient cases

METHODS

A systematic review of literature on MEDLINE, Google Scholar, and the Cochrane Database of Systematic Reviews for RSD case studies to assess post-operative hypertension readings and medical management.

RESULTS

Among 51 RSD cases, the post-operative RSD patients report an apparent reduction with a mean number of 3.1 antihypertensive medications. The mean systolic arterial blood pressure 1 year following RSD was 136.0 mmHg (CI: 118.7 - 153.3).

CONCLUSION

The apparent improvements in office systolic blood pressure after 12 mo post-operative RSD can support the therapeutic potential of this intervention for blood pressure reduction. Additional studies which utilized a uniform methodology for blood pressure measurement can further support the findings of this systematic review.

Key Words: renal denervation; hypertension; systematic review; interventional radiology; outcomes

Singh SP, Varghese KJ, Qureshi FM, Anderson MC, Foxworth J, Knuepfer MM. Catheter-based Renal Sympathetic Nerve Denervation on Hypertension Management Outcomes. *World J Radiol* 2022; In press

Core Tip: This is the first systematic review focused on peer-reviewed clinical case reports in the topic area of renal sympathetic denervation (RSD) in hypertension outcomes. In addition, this study has noted the changes in blood pressure medication regimens for the management of resistant hypertension.

INTRODUCTION

Hypertension continues to be a pressing health condition worldwide. Despite widespread use of antihypertensive medications, it is estimated that only 24% of the patients who are prescribed these medications currently have their blood pressures controlled ^[1-2]. It is estimated that between 10 and 15% of patients with hypertension ² do not achieve adequate blood pressure control, despite the use of at least three antihypertensive agents ^[1-2]. Moreover, this group of patients is designated as having resistant hypertension ^[2]. Let alone, patients with true resistant hypertension bear a greater risk for mortality compared to the general population [3-5]. In fact, rates of cardiovascular events correlate with mean 24-hour ambulatory blood pressures, which

further justifies the pressing need to innovate medical management of this condition [5]. Similarly, non-adherence to anti-hypertensive therapy is a significant problem that limits the success of drug therapies [6]. As such, the need for additional intervention beyond medication in patients with resistant hypertension is apparent.

Renal sympathetic denervation (RSD) has been proposed as a potential solution to control arterial pressure. Moreover, RSD is a catheter-based renal denervation which employs transvascular ablation of the renal sympathetic nerves using radiofrequency energy to interrupt both sensory and motor nerves through the renal arterial wall. The earliest clinical studies on RSD demonstrated a significant reduction in arterial pressure in most patients [7-9]. However, the body of evidence has largely been in dispute as to what the true postoperative outcomes are regarding this novel procedure. In fact, the SYMPPLICITY HTN-3 clinical trial did not show a benefit for patients treated with the procedure compared to the sham group [10]. This has prompted the numerous additional studies of the effects of RSD. Most of these studies have reported reductions of ambulatory blood pressure, but the extent and location of ablation sites have varied considerably [10-12]. The efficacy of this procedure is difficult to evaluate due to widely varying levels of denervation and often the lack of appropriate control groups [11]. Despite this paucity in evidence, there have been a number of clinical cases reported in peer-reviewed literature which showcase the utilization of catheter-based renal denervation. However, there has not been a systematic review of these cases to consolidate the findings. ¹ Therefore, the aim of this study is to assess the efficacy of RSD treatment in attenuating systolic blood pressures and reducing antihypertensive agents among patients with resistant hypertension.

MATERIALS AND METHODS

Study Design and Inclusion

A systematic review of literature was performed on MEDLINE, Google Scholar, and the Cochrane Database of Systematic Reviews for renal denervation case studies. This study methodology was registered by PROSPERO International prospective register of

systematic reviews (National Institute for Health Research). The search was performed following the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines and checklist.³ Contingent valuation studies within renal denervation procedures were identified using search terminologies that combined the following epidemiological terms: renal sympathetic denervation, renal sympathetic ablation, hypertension renal denervation, renal denervation case studies, renal denervation case reports. Variations of the terms were also used when deemed necessary by the reviewers (e.g. “study” vs. “studies”).

The initial search yielded 368 articles. Duplicates were removed, and then each article was reviewed for the following inclusion criteria: English language, case reports, full-text, pertinence to renal denervation procedures, and peer-reviewed (Figure 1). In addition, the reference list of each identified study was also reviewed to further ensure that all appropriate studies were identified. No further articles met the inclusion criteria. This qualitative synthesis yielded 62 articles.

Data Extraction and Evaluation

Each study included was independently appraised by three reviewers (S.P.S., K.J.V., F.M.Q) for literature quality and categorical data including: patient age, sex, ethnicity, height, weight, hypertension diagnosis, years hypertensive, blood pressure reading prior to renal denervation, presentation to emergency department, medications prior to renal denervation procedure, previous treatments related to hypertension, past medical/social/family history, renal denervation approach, number of lesions, duration of lesion/ablation, brand name of ablation catheter, bilateral (Y/N), renal artery length/diameter(s), days until discharge, blood pressure readings on follow-up, post-treatment medications, success in attenuating hypertension, and complications post-procedure. If there was any discrepancy between the three reviewers, discussion was conducted, and final determination was made by S.P.S. Meta-analyses were not performed due to a heterogeneity in reporting methodologies.

Statistical Analysis

Statistical analysis was performed using Stata 14 Statistical Package (StataCorp, College Station, Texas) for descriptive statistics on the variables of interest including counts, percentages, means and standard deviations where appropriate. ANOVA calculations were performed to determine significance between variable groups of interest. The level of significance was set at $p < 0.05$.

RESULTS

The systematic review identified 368 records through the search methodology (Figure 1). After duplicates were removed, 94 records remained and 66 of those records were then screened and assessed for eligibility. This left a total of 43 complete studies to be included in the qualitative synthesis. Three of these studies included multiple patients. In total, 51 patient cases involving renal denervation procedures for hypertension were extracted from the 43 studies examined. The articles included in this study were published between 2012 and 2021. The peak year for case study reports was 2015 ($n = 12$), followed by 2013 ($n = 11$), 2012 ($n = 7$), 2014 ($n = 6$), 2017 and 2018 ($n = 4$), 2021 ($n = 3$), 2019 and 2020 ($n = 1$), respectively.

Among patients treated with RSD, 24 were female, 27 were male. ¹ The mean age of the patient population was 49.9 years (CI: 44.9 - 55.0) with the youngest being 6 years and the oldest being 83 years. Among sexes, the mean age of females was 50.1 (CI: 41.7 - 58.5) and for males was 49.5 (CI: 43.3 - 55.8). The mean body mass index (BMI) of the patient population was 31.3 (CI: 27.4 - 35.2). Among sexes, the mean BMI of females was 31.6 (CI: 25.3 - 37.9) and males was 31.0 (CI: 24.7 - 37.3).

The reviewers identified the terminology used for diagnosis of hypertension for each of the 51 patients studied and stratified these to identify 40 patients with resistant hypertension. Additionally, not all studies reported the number of years patients were hypertensive prior to RSD. Among those that did, the total patient population had a mean duration of diagnosed hypertension of 10.1 years (CI: 4.5 - 15.8), with the mean for males being 8.1 years (CI: -1.2 - 17.4) and females being 11.8 years (CI: 2.4 - 21.2).

Additionally, of the patients diagnosed with resistant hypertension, the mean decreases to 7.8 years (CI: 3.4 - 12.1).

Two patients underwent RSD treatment following a presentation of hypertensive crisis in the Emergency Department. Six patients reported a history of diabetes (Type 1: $n = 1$; Type 2: $n = 5$). Another 4 patients reported polycystic kidney disease. One patient reported fibromuscular dysplasia. Histories of myocardial infarctions, hypercholesterolemia and hyperlipidemia were not compiled due to variations in reporting these potential contributing factors. No patient underwent RSD before the case report. Prior to RSD treatment, patient histories reported a mean number of 4.7 antihypertensive medications (CI: 4.1 - 5.4) as shown in Table 3.

The mean standard office blood pressure of patients prior to RSD treatment was assessed. The mean systolic blood pressure was 172.7 mmHg (CI: 165.1 - 180.3) among the entire patient population, and 171.4 mmHg (CI: 162.3 - 180.4) among those with resistant hypertension. Females had a mean systolic blood pressure of 170.2 mmHg (CI: 158.2 - 183.3), and males had a mean of 175.5 mmHg (CI: 164.7 - 186.3).

The first-generation SYMPPLICITY renal denervation catheter® (Medtronic, Dublin, Ireland) was the most commonly used, being identified in 57.5% of cases ($n = 40$). This frequency was greater than EnligHTN renal artery ablation catheter® (St. Jude Medical, Inc., Saint Paul Minnesota) at 15%. The remaining cases used other available treatments. The mean number of ablations on the left renal artery was 5.0 (CI: 3.2 - 6.8), and the right renal artery was 5.3 (CI: 3.5 - 7.2). The reported duration of an ablation varied among each study, noting the shortest duration at 10 s, and longest duration at 120 s.

Four studies reported discharge from the hospital within 24 h of treatment.

Three studies reported renal artery stenosis in at least 1 artery during follow up appointments. One study noted progression into aortic stenosis. Two studies reported aortic dissection, one occurring during the operation, and the second reported the dissection twenty-two months post-operatively. In both cases, the dissection was deemed unrelated to the RSD procedure. Episodes of hypertensive crises post-treatment were not reported in any of the case studies. In addition, the mean standard office

blood pressure (BP) of patients ¹ post-RSD treatment was assessed. The mean post-operative systolic blood pressure of reported cases was reported at 24 hrs, 1 mo, 3 mo, 6 mo and 1 year after surgery (Table 2). The arterial pressure appeared to be significantly reduced although all measurements were not done at all time points in all these studies. After RSD treatment, patient follow-up histories in some reports described an apparent reduction with a mean number of 3.1 antihypertensive medications (CI: 2.3 - 3.9) in all patients (Table 3).

DISCUSSION

T

The aim of this systematic review of case reports was to examine the postoperative efficacy of RSD on blood pressure reduction in patients with resistant hypertension and evaluate the change in antihypertensive medication regimen. Overall, the therapeutic potential that this catheter-based procedure provides in attenuating hypertension merits its exploration. This search for contemporary case studies published in English medical journals yielded 48 patient cases which reviewers utilized to draw conclusions. The focus of this study is to determine the effect of RSD on blood pressure attenuation in hypertensive patients. Based on the ³ most recent European Society of Cardiology (ESC) and the European Society of Hypertension (ESH) guidelines for the management of arterial hypertension, which classifies arterial blood pressures into grades ^[12], the mean standard office systolic blood pressure of patients prior to RSD treatment was between 160-179, or grade 2 hypertension, and ≥180, or grade 3 hypertension, among the patient population as a whole. ¹ The mean 24-hour post-operative systolic blood pressure of reported cases was in grade 2 hypertension. At 1, 3, 6, and 12-month follow-up, the mean systolic arterial pressure of reported cases remained in grade 1 hypertension (systolic blood pressure between 140-159). For the majority of patients, ¹ the severity of hypertension declined from borderline-malignant hypertension to grade I hypertension. The resulting reduction in arterial pressure during these follow up visits are consistent with the results of larger renal denervation trials [7-9, 12-13].

Regarding the current body of literature, the SYMPPLICITY HTN-3 clinical trial which was performed in the U.S. reported the lack of a sustained reduction in arterial pressure after RSD [10]. Despite the observations in other studies showing reductions maintained for at least three years, the consistency of arterial pressure reduction has been controversial. There were similar observations in the case reports reviewed here, but the overall findings note a net reduction in blood pressure at one year follow up. In addition, the intention to evaluate the office systolic blood pressure readings is further supported by contemporary literature as a modality to objectively evaluate blood pressure reduction effects. [14].

The most common instrument used in these studies was the first generation, radiofrequency device (Symplicity, Medtronic ®). During the initial studies with this instrument, it was recommended that the device be advanced to the first bifurcation of the renal artery allowing for 3-6 RF lesions on each renal artery. Subsequent studies have shown that this has highly variable effects on depletion of renal catecholamines [15]. Additionally, it has been shown that the renal nerves are more closely apposed to the renal artery in the distal segments [16]. This has led to the development of smaller catheters with multiple electrode sites that can be advanced farther into the renal artery and are able to make many more focal lesions [17]. This has likely improved the success of the actual denervation making the second-generation devices more effective in RSD.

Contemporary clinical guidelines encourage a stepwise approach, involving combination therapy, in order to increase the number and doses of medications when treating hypertension. Additionally, this is also with the understanding that every drug has a limited capacity for blood pressure reduction [18-19]. Therefore, patients described in these reports with grade 2 or 3 hypertension were typically on several medications. Since it is known that adherence to antihypertensive drug therapy is poor [6], the permanence of the RSD treatment offers a significant advantage, including reducing drug therapies in some patients and thereby improving compliance. These case reports were encouraging in this regard, as this study reported an average reduction by one-to-two medications from the patient's regimen. Furthermore, chronic

administration of common antihypertensives can lead to adverse effects such as impotence with beta-blockers or angioedema with ACE inhibitors. Therefore, a desirable characteristic of RSD is a corresponding reduction in pharmacotherapy leading to improved compliance and reduced side effects.

Several case studies detailed complications of RSD, particularly associated with renal artery stenosis. While these were not deemed a major risk, the outcome can exacerbate hypertension. Furthermore, renal artery stenosis is a contraindication for medications such as ACE inhibitors or angiotensin receptor blockers. The combination of drug therapy and inhibiting Angiotensin II can significantly reduce renal function, particularly in the context of kidney disease. This study proposes the close monitoring of the renal arteries at the follow-up visits post-RSD treatment to track and quickly counter the occurrence of renal artery stenosis.

While the first U.S.-based trial (SYMPPLICITY HTN-3) reported a reduction in arterial pressure in treated patients that was the same as the reduction observed in control patients^[10], RSD has not been approved in the United States. Clinicians in the U.S. have a wealth of data because practitioners in other countries have been using RSD to treat resistant hypertension for nearly a decade. The International Sympathetic Nervous System Summit evaluated the future of RSD. The author's conclusions include an expected 10 mmHg decrease in blood pressure and 25% decrease in overall cardiovascular events [20]. Furthermore, a large meta-analysis comparable to this review established similar findings. Warchol-Celinska *et al* included 613,815 patients from 122 studies to find a reduction of office systolic blood pressure by 10 mmHg, cardiovascular events by 20%, and overall mortality by 13% [7]. Adding our study to the current conversation supports the notion that RSD is an intervention with significant advantages. It would be most beneficial to perform additional randomized control trials to acquire definitive evidence of the antihypertensive effects of RSD treatment.

CONCLUSION

Renal sympathetic denervation is a procedure that can manage resistant hypertension while avoiding the complications of drug adherence. Benefits of the procedure include sustainable attenuation of arterial pressure, reduced dependence on medications leading to fewer side effects, and to a reduction in the inherent diseases associated with hypertension. One limitation encountered in this analysis is that the antihypertensive medications detailed were only evaluated based on the quantity, dose or number that a patient was taking, not based on the class or mechanism of action. Furthermore, as all included articles were case studies, which can effect the validity of these results to translate into clinical reasoning and practice. Despite this, this study recognizes that there is a need for more randomized control trials to establish the benefits of RSD, duration of effectiveness, incidence of complications, and improvement in all-cause mortality. Finally, findings of irregular attenuation of arterial pressure are likely confounded by improved quality of denervation afforded by newer devices. This procedure offers a viable option to control blood pressure with significant advantages over current treatments that could improve the effectiveness of the treatment of hypertension.

ORIGINALITY REPORT

5%

SIMILARITY INDEX

PRIMARY SOURCES

1

S. SINGH, K. Varghese, S. Majagi, F. Qureshi, J. Foxworth, M. Knuepfer. "POS-413 MANAGEMENT OF HYPERTENSION AFTER RENAL SYMPATHETIC DENERVATION IN MALE PATIENTS", Kidney International Reports, 2021

Crossref

116 words — 4%

2

A Oliveras, A de la Sierra. "Resistant hypertension: patient characteristics, risk factors, co-morbidities and outcomes", Journal of Human Hypertension, 2013

Crossref

23 words — 1%

3

www.ncbi.nlm.nih.gov

Internet

20 words — 1%